Johnson Pharmacare Ltd (JOHNPHARMA) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Johnson Pharmacare Ltd on NSE and BSE, with an AI summary of each filing.
Undertaking for non - applicability of reg 32 of sebi (lodr) reg 2015
Others (Uncategorized) · 14 Aug 2026, 12:58 am
Johnson Pharmacare: No Capital Raising Activity in Q1 FY27 Johnson Pharmacare Limited (BSE: 532154) filed a notice on 13-Aug-26 confirming the non-applicability of SEBI's Regulation 32 for the quarter ended 30-Jun-26. The company certified it had not raised funds through a public issue, rights issue, or preferential issue during the period. Therefore, the requirement to provide a statement of deviation or variation in the use of proceeds is not applicable. This confirms no new equity fundraising occurred in Q1 FY27.
Submission of Un-Audited Financial Results for the Quarter ended on June 30th 2026 and along with Limited Review Report Thereon.
Financial Result · 14 Aug 2026, 12:51 am
Johnson Pharmacare Reports Net Loss of ₹110.31 Lakhs for Q1FY27 Johnson Pharmacare posted a net loss of ₹110.31 lakhs for the quarter ended 30th Jun'26, compared to a loss of ₹5.34 lakhs in the prior year period. Total income was nil, down from ₹158.10 lakhs YoY. The quarter's loss follows a significant loss of ₹5,561.06 lakhs in Q4FY26, which included a ₹1,427 lakh exceptional item. Total expenses for Q1FY27 were ₹110.31 lakhs versus ₹5.34 lakhs YoY. Basic and diluted EPS stood at (₹0.02) against (₹0.00) in the corresponding quarter.
UN-AUDITED FINANCIAL RESULTS The Board of Director have considered and approved the Un-Audited Financial Results along with Limited Review Report thereon for quarter ended on June 30th, ....
Outcome · 14 Aug 2026, 12:42 am
Johnson Pharmacare Ltd - Financial Result for the Quarter ended 30th Jun'26 (Standalone, INR Lakh) ■ Revenue: 0.0 ■ EBITDA: -4.1 (+22.5% YoY | +99.9% QoQ) ■ EBITDA Margin (%): 0.0 ■ PAT: -110 (-1965.7% YoY | +98.0% QoQ) ■ EPS (INR): -0.02 (+98.0% QoQ)
The Exchange and Investors are hereby informed that boards of directors of the company had accorded thier approval for shifting of Registered Office of the Company from Existing Address ....
Others (Uncategorized) · 12 Aug 2026, 2:22 am
Johnson Pharmacare Announces Change of Registered Office Johnson Pharmacare's Board of Directors approved the relocation of its registered office within Ahmedabad on 11 Aug'26. The new address is Shop No. I-460, Fourth Floor, Titanium City Centre Mall, Satellite, Ahmedabad – 380015. The move is from the previous location at Vardan Tower, Navrangpura, Ahmedabad. This change is a corporate disclosure under SEBI's Listing Obligations and Disclosure Requirements Regulations, 2015.
Johnson Pharmacare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2026 ,inter alia, to consider and approve To consider and approve ....
Intimation · 13 Aug 2026, 5:30 am
Johnson Pharmacare Board to Approve Q1FY27 Results on 13th Aug'26 Johnson Pharmacare (BSE: 532154) has scheduled a Board of Directors meeting on 13th Aug'26 to consider and approve its un-audited standalone financial results for the quarter ended 30th Jun'26. In connection with this, the trading window for company insiders has been closed since 01st Jul'26 and will reopen 48 hours after the results are declared.
Submission of Audited Financial Results of Jhonson Pharmacare ltd for the quarter and year ended on March 31st March 2026
Financial Result · 20 Jun 2026, 12:11 am
Johnson Pharmacare Ltd - Financial Result for the Quarter ended 31st Mar'26 (Standalone, INR Lakh) ■ Revenue: 0.0 ■ EBITDA: -4,270 (-520661.0% YoY | -178571.1% QoQ) ■ EBITDA Margin (%): 0.0 ■ PAT: -5,561 (-10736.0% YoY | -86791.6% QoQ) ■ EPS (INR): -1.01 (-10000.0% YoY)
Pursuant to Regulation 30 of SEBI (LODR) Regulations 2015 there is change.
Change in Management · 12 Jun 2026, 7:50 pm
Johnson Pharmacare Company Secretary Resigns Johnson Pharmacare (BSE: 532154) announced the resignation of its Company Secretary and Compliance Officer, Ms. Neha Srivastava (Membership No. ACS43927), effective 11 Jun'26. The company stated the reason for her departure was personal and unavoidable. Ms. Srivastava confirmed there were no other material reasons for her resignation. This change in key management personnel was disclosed as per Regulation 30 of SEBI (LODR) Regulations, 2015.
meeting of board of director to considered and approved the following 1.audited financial results 2. Statement of deviation or variation 3. take note on resignation of Rajendra prasad (Non- ....
Outcome · 01 Jun 2026, 7:18 pm
Johnson Pharmacare FY26 Results; Notes Director Resignations Johnson Pharmacare's Board approved audited financial results for the quarter and year ended 31 Mar'26. For FY26, the company reported a net loss of ₹5,573.39 lacs versus a loss of ₹58.38 lacs YoY. Q4FY26 net loss was ₹5,561.06 lacs compared to a ₹51.32 lac loss in Q4FY25. Total assets stood at ₹2,203.11 lacs. The Board also noted the resignations of Rajendra Prasad, Non-Executive Director, and Umesh Kumar, Executive Director, both effective 17 Apr'26, due to personal reasons.
DIsclosure of RPT
Others (Uncategorized) · 28 May 2026, 1:27 am
Johnson Pharmacare Reports No Related Party Transactions for FY26 Johnson Pharmacare Limited informed BSE on 27 May'26 that it had not entered into any Related Party Transactions (RPTs) for the financial year ended 31 Mar'26. The disclosure, filed under Regulation 23(9) of SEBI (LODR) Regulations, 2015, confirmed that the company had a NIL balance for RPTs during the reporting period. This filing follows the SEBI format mandated from 22 Nov'21.
Undertaking for Non- Applicability of Regul;ation 32 of SEBI (LODR) Regulation 2015 for the quarter and financial year ended 31st March 2026
Others (Uncategorized) · 28 May 2026, 1:25 am
Johnson Pharmacare Confirms Non-Applicability of SEBI Fund Utilization Rule Johnson Pharmacare Limited informed the BSE on 27-May'26 that Regulation 32 of SEBI (LODR) Regulations, 2015, is not applicable for the quarter and year ended 31-Mar'26. The company certified it had not raised funds through any public issue, rights issue, or preferential issue during this period. Therefore, the requirement to submit a statement of deviation or variation in the use of public issue proceeds does not apply. This is a compliance update confirming no recent equity fundraising activity.
Submission of audited financial results for the quarter and financial year ended 3st March 2026
Financial Result · 28 May 2026, 1:23 am
Johnson Pharmacare Reports Widened Q4 and FY26 Losses Johnson Pharmacare reported a net loss of ₹5,561.06 lacs for Q4 ended 31 Mar'26, compared to a loss of ₹51.32 lacs YoY. FY26 net loss widened significantly to ₹5,573.39 lacs from ₹58.38 lacs in FY25, primarily driven by a ₹1,427.00 lac exceptional item loss and a surge in other expenses. Total assets declined to ₹2,203.11 lacs from ₹5,792.59 lacs YoY. Basic EPS for FY26 stood at negative ₹1.01. The auditor's report noted non-compliance with Indian Accounting Standards and highlighted significant cash losses.
Submission of audited financial results for the quarter and financial year ended 3st March 2026
Financial Result · 28 May 2026, 1:22 am
Johnson Pharmacare Reports Significant FY26 Net Loss and Negative Equity Johnson Pharmacare reported a net loss of ₹5,573.39 lacs for FY26, a steep decline from the ₹58.38 lacs loss in FY25. The Q4 FY26 net loss was ₹5,561.06 lacs versus a loss of ₹51.32 lacs YoY. The full-year loss was driven by a ₹1,427.00 lacs exceptional item and a significant increase in other expenses. Total assets decreased to ₹2,203.11 lacs from ₹5,792.59 lacs YoY. Total equity turned negative to ₹43.52 lacs as of 31 Mar'26, down from ₹5,616.91 lacs in the prior year.
Pursuant to the provisions of Regulation 30 and other applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that the meeting ....
Outcome · 28 May 2026, 1:16 am
Johnson Pharmacare Ltd - Financial Result for the Quarter ended 31st Mar'26 (Standalone, INR Lakh) ■ Revenue: 0.0 ■ EBITDA: -4,270 (-520661.0% YoY | -178571.1% QoQ) ■ EBITDA Margin (%): 0.0 ■ PAT: -5,561 (-10736.0% YoY | -86791.6% QoQ) ■ EPS (INR): -1.01 (-10000.0% YoY)
Johnson Pharmacare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/05/2026 ,inter alia, to consider and approve To consider and approve ....
Intimation · 27 May 2026, 5:30 am
Johnson Pharmacare Board Meeting on 27th May'26 for Q4FY26 Results Johnson Pharmacare Ltd (BSE: 532154) has scheduled a Board of Directors meeting on 27th May'26 to consider and approve the audited financial results for the quarter and year ended 31st Mar'26. In connection with this, the trading window for company insiders has been closed since 01st Apr'26 and will reopen 48 hours after the financial results are declared. The meeting will address the approval of the Q4FY26 and full-year FY26 financial statements, which is a key event for investors.
<b>Format of the Annual Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''> <tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> ....
Others (Uncategorized) · 09 May 2026, 11:49 pm
Johnson Pharmacare Confirms It Is Not A Large Corporate Johnson Pharmacare, in a disclosure dated 9th May '26 for the year ended 31st Mar '26, confirmed it is not classified as a Large Corporate under SEBI's framework. The company stated it does not meet the specified threshold limits outlined in the SEBI circular dated 19th Oct '23. Consequently, the mandatory borrowing requirements through debt securities for Large Corporates are not applicable to the company for the financial year 2025-26. The filing reported no incremental or mandatory borrowing for the period.
<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
Others (Uncategorized) · 30 Apr 2026, 11:24 pm
Johnson Pharmacare Confirms It Is Not a Large Corporate for FY26 Johnson Pharmacare Limited (BSE: 532154) has formally declared it does not qualify as a "Large Corporate" for the financial year 2025-26, according to SEBI's circular criteria. The filing on 30th Apr'26 confirms the company is not subject to the mandatory debt fundraising requirements for large entities. As of the last reporting period, the company had outstanding borrowings of ₹0.00 Cr and no credit rating, reinforcing its status outside the framework. This relieves the company of any obligation to raise funds via debt securities.
Disclosure as per Regulation 30 of SEBI (LODR) Regulation 2015
Change in Management · 18 Apr 2026, 12:50 am
Johnson Pharmacare Announces Two Director Resignations Johnson Pharmacare announced the resignation of two board members effective 17th Apr'26. Mr. Rajender Parsad has resigned as an Additional & Non-Executive Director, and Mr. Umesh Kumar has resigned as an Additional & Executive Director. Both resignations were attributed to personal reasons, with confirmations that no other material reasons exist for their departure. The board approved both resignations during its meeting on 17th Apr'26. Both outgoing directors also hold directorships at Space Incubatrics Technologies Limited.
Disclosure as per Regulation 30 of SEBI (LODR) Regulation 2015 Appointment of MR. Nand Kishore Ray as Additional Non -Executive &Non- Independent Director and Appointment of mr. Dheeraj ....
Change in Management · 18 Apr 2026, 12:25 am
Johnson Pharmacare Appoints Two New Board Directors Johnson Pharmacare's Board of Directors has approved two new appointments effective 17th Apr'26. Mr. Nand Kishore Ray (DIN: 11626638) joins as an Additional (Non-Executive & Non-Independent) Director. Additionally, Mr. Dheeraj Kumar (DIN: 11666616) has been appointed as an Additional (Executive) Director. The company confirms no inter-se relationships between the new appointees and existing directors. Both appointees have provided non-debarment declarations as per SEBI regulations. This move strengthens the company's governance and executive leadership.
1. The Board has appointed Mr. Nand Kishore Ray (DIN: 11626638) as an Additional (Non-Executive & Non-Independent Director) of the Company w.e.f 17th April, 2026 The Board has appointed ....
Others (Uncategorized) · 17 Apr 2026, 11:38 pm
Johnson Pharmacare Board Reshuffled with New Appointments and Resignations Johnson Pharmacare announced board changes effective 17th Apr'26. Nand Kishore Ray joins as an Additional Non-Executive & Non-Independent Director and Dheeraj Kumar is appointed as an Additional Executive Director. Concurrently, the board approved the resignations of Rajender Parsad (Additional & Non-Executive Director) and Umesh Kumar (Additional & Executive Director). Both resignations were cited for personal and unavoidable reasons. All changes are effective from the same date, indicating a significant board reconstitution for the company.
Disclosure as per Regulation 30 of SEBI LODR Regualtion 2015 for the appointment of Additional Non- Executive & Independent Director.
Change in Management · 17 Feb 2026, 11:56 pm
Johnson Pharmacare Appoints New Independent Director to Board Johnson Pharmacare announced the appointment of Ms. Parul Agrawal (DIN: 11268580) as an Additional Non-Executive & Independent Director, effective 13th Feb'26. The decision was made at the Board of Directors meeting on the same day. Ms. Agrawal's brief profile lists her as a Company Secretary. The company confirmed she is not related to any existing Directors or Key Managerial Personnel and is not debarred from holding a directorship by any regulatory authority, including SEBI.
Disclosure as per Regulation 30 of SEBI LODR Regulation 2015 for the appointment of Statutory Auditor.
Change in Auditor · 17 Feb 2026, 11:49 pm
Johnson Pharmacare Appoints M/S. VRSK & Associates as Statutory Auditor Johnson Pharmacare's Board of Directors, in a meeting on 13th Feb'26, approved the appointment of M/S. VRSK & Associates (FRN: 011199N) as the new Statutory Auditor. The appointment fills a casual vacancy and is effective immediately. The terms of the appointment will be valid up to the next ensuing general meeting. This decision follows SEBI's Listing Obligations and Disclosure Requirements regulations.
Revised outcome of Meeting of Board of Directors held on Friday 13th Feburay 2026 at Pursuant to Regulation 30 of SEBI LODR Regulation 2015.
Revision of outcome · 17 Feb 2026, 11:26 pm
Johnson Pharmacare Appoints New Auditor and Independent Director Johnson Pharmacare's Board of Directors, in its meeting on 13th Feb'26, approved key appointments. M/S. VRSK & Associates (FRN: 011199N) was named Statutory Auditor to fill a casual vacancy, effective 13th Feb'26. Additionally, Ms. Parul Agrawal (DIN: 11268580) was appointed as an Additional Non-Executive & Independent Director, also effective 13th Feb'26. These changes are crucial for the company's governance and financial oversight framework. Both appointees have provided necessary consent and declarations as per regulatory requirements.
Undertaking for Non- applicability of reg 32 of sebi (lodr) regualtion 2015 for the quarter ended on 31st December 2025
Others (Uncategorized) · 14 Feb 2026, 11:50 pm
Johnson Pharmacare Confirms Non-Applicability of SEBI Fund Utilization Rule for Q3FY26 Johnson Pharmacare Limited (BSE: 532154) submitted an undertaking to the BSE stating that Regulation 32 of SEBI (LODR) Regulations, 2015 is not applicable for the quarter ended 31st Dec'25. This regulation mandates reporting on the use of proceeds from capital raises. The company confirmed it had not issued shares via a rights issue, public issue, or preferential allotment during the specified quarter, thus negating the requirement to file a statement on fund utilization or deviations.
Submission of unaudited (Stanalone) Financials results of (Johnson Pharmacare Limited) for the quarter ended on 31st December 2025 along with limited Review Report Thereon.
Financial Result · 14 Feb 2026, 11:45 pm
Johnson Pharmacare Reports Net Loss of ₹6.40 Lakh for Q3 FY26 Johnson Pharmacare Limited reported a net loss of ₹6.40 lakh for the quarter ended 31st Dec'25, widening from a loss of ₹2.99 lakh in the corresponding quarter last year. The company recorded nil revenue from operations. Total expenses for the quarter stood at ₹6.40 lakh, up from ₹2.99 lakh YoY, driven by higher employee benefits, depreciation, and other expenses. For the nine months ended 31st Dec'25, the net loss was ₹12.34 lakh compared to ₹7.06 lakh YoY. The Board approved the results on 14th Feb'26.
UNAUDITED (STANDALONE) FINANCIAL RESULTS The Board of Director have considered and approved the Unaudited (Standalone) Financial Results along with Limited Review Report thereon for the ....
Outcome · 14 Feb 2026, 11:36 pm
JOHNSON PHARMACARE LIMITED - Financial Result for the Quarter ended 31st Dec'25 (Standalone, INR Lakhs) ■ Revenue: 0.0 ■ EBITDA: -4.2 (-837.8% YoY | -1306.7% QoQ) ■ EBITDA Margin (%): 0.0 ■ PAT: -6.4 (-114.0% YoY | -1782.4% QoQ) ■ EPS (INR): 0.00